Acadian Asset Management
RCKT icon

Acadian Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Acadian Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-242,169
Closed -$847K – 2216
2025
Q4 		$847K Buy
242,169
+32,323
+15% +$111K ﹤0.01% 1153
2025
Q3 		$681K Sell
209,846
-88,059
-30% -$277K ﹤0.01% 1142
2025
Q2 		$728K Buy
+297,905
New +$1.51M ﹤0.01% 1059
2024
Q4 		– Sell
-3,553
Closed -$65K – 2062
2024
Q3 		$65K Buy
+3,553
New +$72.8K ﹤0.01% 1730
2018
Q1 		– Sell
-7,320
Closed -$76K – 1804
2017
Q4 		$76K Buy
+7,320
New +$72.6K ﹤0.01% 1154
2016
Q1 		– Sell
-10,207
Closed -$462K – 1470
2015
Q4 		$462K Sell
10,207
-8,905
-47% -$388K ﹤0.01% 819
2015
Q3 		$718K Buy
+19,112
New +$877K ﹤0.01% 726

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management's RCKT Position: Q1 2026 in Review

Acadian Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 242,169 shares — an estimated $847K sold.

Acadian Asset Management first reported a position in RCKT in Q3 2015 and held it in 7 quarters. The position peaked at $847K in Q4 2025. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • Acadian Asset Management reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 242,169 Rocket Pharmaceuticals shares in Q1 2026, an estimated $847K.
  • Acadian Asset Management first reported a position in Rocket Pharmaceuticals in Q3 2015 and held it in 7 quarters.
  • Acadian Asset Management's Rocket Pharmaceuticals position peaked at $847K in Q4 2025.
  • 199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.